KR20200103658A - 실조증을 치료하기 위한 릴루졸 전구약물의 용도 - Google Patents

실조증을 치료하기 위한 릴루졸 전구약물의 용도 Download PDF

Info

Publication number
KR20200103658A
KR20200103658A KR1020207016775A KR20207016775A KR20200103658A KR 20200103658 A KR20200103658 A KR 20200103658A KR 1020207016775 A KR1020207016775 A KR 1020207016775A KR 20207016775 A KR20207016775 A KR 20207016775A KR 20200103658 A KR20200103658 A KR 20200103658A
Authority
KR
South Korea
Prior art keywords
ataxia
patient
riluzole
administered
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207016775A
Other languages
English (en)
Korean (ko)
Inventor
블라디미르 코릭
로버트 버만
멜리사 베이너
길버트 리탈리엔
Original Assignee
바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66438598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20200103658(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. filed Critical 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디.
Priority to KR1020257006278A priority Critical patent/KR20250034521A/ko
Publication of KR20200103658A publication Critical patent/KR20200103658A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207016775A 2017-11-12 2018-11-11 실조증을 치료하기 위한 릴루졸 전구약물의 용도 Ceased KR20200103658A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257006278A KR20250034521A (ko) 2017-11-12 2018-11-11 실조증을 치료하기 위한 릴루졸 전구약물의 용도

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762584856P 2017-11-12 2017-11-12
US62/584,856 2017-11-12
US201862717948P 2018-08-13 2018-08-13
US62/717,948 2018-08-13
PCT/US2018/060232 WO2019094851A1 (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257006278A Division KR20250034521A (ko) 2017-11-12 2018-11-11 실조증을 치료하기 위한 릴루졸 전구약물의 용도

Publications (1)

Publication Number Publication Date
KR20200103658A true KR20200103658A (ko) 2020-09-02

Family

ID=66438598

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207016775A Ceased KR20200103658A (ko) 2017-11-12 2018-11-11 실조증을 치료하기 위한 릴루졸 전구약물의 용도
KR1020257006278A Pending KR20250034521A (ko) 2017-11-12 2018-11-11 실조증을 치료하기 위한 릴루졸 전구약물의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257006278A Pending KR20250034521A (ko) 2017-11-12 2018-11-11 실조증을 치료하기 위한 릴루졸 전구약물의 용도

Country Status (26)

Country Link
US (3) US20210023061A1 (https=)
EP (4) EP4483956B1 (https=)
JP (2) JP7352542B2 (https=)
KR (2) KR20200103658A (https=)
CN (1) CN112292127A (https=)
AU (1) AU2018364749C1 (https=)
BR (1) BR112020009173A2 (https=)
CA (1) CA3082096A1 (https=)
DK (2) DK3706739T3 (https=)
ES (1) ES2996892T3 (https=)
FI (2) FI3706739T3 (https=)
HR (1) HRP20241675T1 (https=)
HU (1) HUE070302T2 (https=)
IL (1) IL274532B2 (https=)
LT (2) LT3706739T (https=)
MD (1) MD3706739T2 (https=)
MX (2) MX2020004678A (https=)
PH (1) PH12020550583A1 (https=)
PL (1) PL3706739T3 (https=)
PT (2) PT3706739T (https=)
RS (1) RS66277B1 (https=)
SG (1) SG11202004332XA (https=)
SI (1) SI3706739T1 (https=)
SM (1) SMT202500022T1 (https=)
WO (1) WO2019094851A1 (https=)
ZA (1) ZA202002626B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140879A1 (en) 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
WO2018031707A1 (en) 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
US20250127789A1 (en) * 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2023230451A2 (en) * 2022-05-23 2023-11-30 Biohaven Therapeutics Ltd. Methods of treating spinocerebellar ataxias
WO2026078657A1 (en) 2024-10-10 2026-04-16 Biohaven Therapeutics Ltd. Prodrugs of riluzole

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
PT1001748E (pt) 1997-07-25 2006-08-31 Alpex Pharma Sa Um processo para a preparacao de um granulado adequado para a preparacao de comprimidos rapidamente desintegraveis na boca
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
ES2292848T3 (es) 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
AU2003211051A1 (en) 2002-02-13 2003-09-04 Michael K. Weibel Drug dose-form and method of manufacture
ATE337003T1 (de) * 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
WO2009146031A1 (en) * 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8613937B2 (en) 2008-10-31 2013-12-24 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use

Also Published As

Publication number Publication date
JP7352542B2 (ja) 2023-09-28
HUE070302T2 (hu) 2025-05-28
US20230355592A1 (en) 2023-11-09
EP4699619A3 (en) 2026-05-06
RS66277B1 (sr) 2025-01-31
US20210023061A1 (en) 2021-01-28
PH12020550583A1 (en) 2021-05-31
CA3082096A1 (en) 2019-05-16
ZA202002626B (en) 2025-02-26
LT4483956T (lt) 2026-04-27
JP2021502392A (ja) 2021-01-28
PT3706739T (pt) 2024-12-04
CN112292127A (zh) 2021-01-29
EP4483956A2 (en) 2025-01-01
MD3706739T2 (ro) 2025-02-28
SI3706739T1 (sl) 2025-03-31
US20230390252A1 (en) 2023-12-07
AU2018364749A1 (en) 2020-07-02
WO2019094851A1 (en) 2019-05-16
DK4483956T3 (da) 2026-03-23
FI4483956T3 (fi) 2026-03-16
US12102618B2 (en) 2024-10-01
IL274532A (en) 2020-06-30
DK3706739T3 (da) 2024-12-02
EP4483956A3 (en) 2025-03-19
EP4696324A3 (en) 2026-05-06
PT4483956T (pt) 2026-03-16
PL3706739T3 (pl) 2025-03-10
SG11202004332XA (en) 2020-06-29
JP2023175823A (ja) 2023-12-12
EP4696324A2 (en) 2026-02-18
EP3706739A4 (en) 2021-08-04
EP4483956B1 (en) 2025-12-31
FI3706739T3 (fi) 2024-12-27
MX2023012640A (es) 2023-11-08
EP4699619A2 (en) 2026-02-25
HRP20241675T1 (hr) 2025-02-14
EP3706739B1 (en) 2024-10-16
LT3706739T (lt) 2024-12-27
KR20250034521A (ko) 2025-03-11
NZ765220A (en) 2023-11-24
IL274532B1 (en) 2024-01-01
ES2996892T3 (en) 2025-02-13
AU2018364749C1 (en) 2024-02-15
SMT202500022T1 (it) 2025-03-12
AU2018364749B2 (en) 2023-11-09
EP3706739A1 (en) 2020-09-16
MX2020004678A (es) 2020-08-13
BR112020009173A2 (pt) 2020-11-03
IL274532B2 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
US12102618B2 (en) Use of riluzole prodrugs to treat ataxias
RS53893B1 (sr) Upotreba biotina za tretman multiple skleroze
MX2011008485A (es) Composiciones y metodos para terapia prolongada con aminopiridinas.
US20240277732A1 (en) Compositions and methods for treating brain-gut disorders
KR20120050512A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
US20230372335A1 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
Krach et al. Traumatic brain injury
US20210315907A1 (en) Compositions and methods for treating brain-gut disorders
HK40118245A (en) Use of riluzole prodrugs to treat ataxias
CN116134048A (zh) 用于治疗神经精神障碍的组合物和方法
HK40033906B (en) Use of riluzole prodrugs to treat ataxias
HK40033906A (en) Use of riluzole prodrugs to treat ataxias
HK40037184A (en) Use of riluzole prodrugs to treat ataxias
EA049071B1 (ru) Применение пролекарств рилузола для лечения атаксии
Datta Pitfalls in the Assessment of Gait Disorders
Riccione et al. Wilson’s Disease Myopathy: A Case Report and Brief Literature Review
CN121175045A (zh) 用于治疗夏科-马里-图思病的组合物和方法
US20200038417A1 (en) Methods and compositions for treating cognitive impairment
WO2025194109A1 (en) Compositions and methods for improving brain function
Lin et al. Rapidly progressive spinal muscular atrophy in an ambulatory 2-year-old male
Plasticity et al. http://researchspace. auckland. ac. nz
Hotel et al. XL Congresso Nazionale LIMPE VII Convegno Nazionale DISMOV-SIN

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20260316

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2020 7016775

Appeal request date: 20250225

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2025101000355

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2025101000355; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : APPEAL AGAINST DECISION TO DECLINE REFUSAL